1932
0
  1. Home
  2. A-Z Publications
  3. Annual Review of Virology
  4. Volume 5, 2018
  5. Article

Annual Review of Virology

Volume 5, 2018

Breaking the Last Chains of Poliovirus Transmission: Progress and Challenges in Global Polio Eradication

Abstract

Since the launch of the Global Polio Eradication Initiative (GPEI), paralytic cases associated with wild poliovirus (WPV) have fallen from ∼350,000 in 1988 to 22 in 2017. WPV type 2 (WPV2) was last detected in 1999, WPV3 in 2012, and WPV1 appeared to be localized to Pakistan and Afghanistan in 2017. Through continuous refinement, the GPEI has overcome operational and biological challenges far more complex and daunting than originally envisioned. Operational challenges had led to sustained WPV endemicity in core reservoirs and widespread dissemination to polio-free countries. The biological challenges derive from intrinsic limitations to the oral poliovirus vaccine: () reduced immunogenicity in high-risk settings and () genetic instability, leading to repeated outbreaks of circulating vaccine-derived polioviruses and prolonged infections in individuals with primary immunodeficiencies. As polio eradication enters its multifaceted endgame, the GPEI, with its technical, operational, and social innovations, stands as the preeminent model for control of vaccine-preventable diseases worldwide.

Keyword(s): immunization, polio eradication, poliomyelitis, poliovirus, vaccine-derived poliovirus, World Health Organization
Loading

Article metrics loading...

/content/journals/10.1146/annurev-virology-101416-041749
2018-09-29
2024-04-25
Loading full text...

Full text loading...

/deliver/fulltext/virology/5/1/annurev-virology-101416-041749.html?itemId=/content/journals/10.1146/annurev-virology-101416-041749&mimeType=html&fmt=ahah

Literature Cited

  1. 1. Cent. Dis. Control Prev. 2001. Apparent global interruption of wild poliovirus type 2 transmission. Morbid. Mortal. Wkly. Rep. 50:222–24
     [Google Scholar]
  2. 2.  Kew OM, Cochi SL, Jafari HS, Wassilak SGF, Mast EE et al. 2014. Possible eradication of wild poliovirus type 3—worldwide, 2012. Morbid. Mortal. Wkly. Rep. 63:1031–33
     [Google Scholar]
  3. 3. Glob. Polio Erad. Init. 2017. Polio this week Rep. Glob. Polio Erad. Init., World Health Organ. Geneva: http://polioeradication.org/polio-today/polio-now/this-week/
  4. 4. Glob. Polio Erad. Init. 2017. Pakistan polio update Rep. Glob. Polio Erad. Init., World Health Organ. Geneva: http://polioeradication.org/news-post/pakistan-polio-update-november-2017/
  5. 5. World Health Organ. 2017. Afghanistan polio update Rep. UNICEF/World Health Organ. Kabul: http://www.emro.who.int/images/stories/afghanistan/Afghanistan_Polio_Quarterly_Update_SEPT_2017_FINAL01112017.pdf
  6. 6. Glob. Polio Erad. Init. 2017. Lake Chad region situation report Rep. Glob. Polio Erad. Init., World Health Organ./UNICEF Geneva: http://polioeradication.org/wp-content/uploads/2017/11/polio-vaccination-lake-chad-situation-report-17102017-en.pdf
  7. 7. Glob. Polio Erad. Init. 2017. Global Polio Eradication Initiative investment case Rep. Glob. Polio Erad. Init., World Health Organ. Geneva: http://polioeradication.org/wp-content/uploads/2017/05/InvestmentCase_20170518_EN.pdf
  8. 8.  de Quadros CA, Andrus JK, Olivé JM, Guerra de Macedo C, Henderson DA 1992. Polio eradication from the Western Hemisphere. Annu. Rev. Public Health 13:239–52
     [Google Scholar]
  9. 9. World Health Assem. 1988. Polio Eradication by the Year 2000 Geneva: World Health Organ.
  10. 10.  Patel M, Cochi S 2017. Addressing the challenges and opportunities of the polio endgame: lessons for the future. J. Infect. Dis. 216:Suppl. 1S1–8
     [Google Scholar]
  11. 11.  Paul JR 1971. A History of Poliomyelitis New Haven, CT: Yale Univ. Press
  12. 12.  Dowdle WR, Cochi SL 2002. Global eradication of poliovirus: history and rationale. Molecular Biology of Picornaviruses BL Semler, E Wimmer 473–80 Washington, DC: ASM Press
     [Google Scholar]
  13. 13.  Eggers HJ 2002. History of poliomyelitis and poliomyelitis research. Molecular Biology of Picornaviruses BL Semler, E Wimmer 3–14 Washington, DC: ASM Press
     [Google Scholar]
  14. 14.  Offit PA 2005. The Cutter Incident: How America's First Polio Vaccine Led to the Growing Vaccine Crisis New Haven, CT: Yale Univ. Press
  15. 15.  Oshinsky DM 2005. Polio: An American Story New York: Oxford Univ. Press
  16. 16.  Ehrenfeld E, Domingo E, Roos R 2010. The Picornaviruses Washington, DC: ASM Press
  17. 17.  Nathanson N, Kew OM 2010. From emergence to eradication: the epidemiology of poliomyelitis deconstructed. Am. J. Epidemiol. 172:1213–29
     [Google Scholar]
  18. 18.  Racaniello VR 2013. Picornaviridae: the viruses and their replication. Fields Virology DM Knipe, PM Howley 453–89 Philadelphia: Lippincott Williams & Wilkins
     [Google Scholar]
  19. 19.  Kew OM 2014. Enteroviruses: polio. Viral Infections of Humans RA Kaslow, LR Stanberry, JW Leduc 277–336 New York: Springer
     [Google Scholar]
  20. 20.  Sutter RW, Kew OM, Cochi SL, Aylward RB 2018. Poliovirus vaccine—live. Vaccines, ed. SA Plotkin, WA Orenstein, PA Offit, KM Edwards 866–917 Philadelphia: Elsevier
  21. 21. Bill & Melinda Gates Found. 2017. What we do: polio, strategy overview Rep. Bill & Melinda Gates Found Seattle, WA: https://www.gatesfoundation.org/What-We-Do/Global-Development/Polio
  22. 22. Cent. Dis. Control Prev. 2017. Global health: polio eradication Rep. Cent. Dis. Control Prev. Atlanta, GA: https://www.cdc.gov/polio/
  23. 23. Rotary Int. 2017. PolioPlus: people of action Rep. Rotary Int. Evanston, IL: https://my.rotary.org/en/take-action/end-polio
  24. 24. UNICEF. 2017. For every child, #VaccinesWork Rep. UNICEF New York: https://www.unicef.org/immunization-programme
    [Google Scholar]
  25. 25.  Pallansch MA, Oberste MS, Whitton JL 2013. Enteroviruses: polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses. Fields Virology DM Knipe, PM Howley 490–530 Philadelphia: Lippincott Williams & Wilkins
     [Google Scholar]
  26. 26.  Hogle JM, Chow M, Filman DJ 1985. The three-dimensional structure of poliovirus at 2.9 Å resolution. Science 229:1358–65
     [Google Scholar]
  27. 27.  Minor PD, Almond JW 2002. Poliovirus vaccines: molecular biology and immune response. Molecular Biology of Picornaviruses BL Semler, E Wimmer 381–90 Washington, DC: ASM Press
     [Google Scholar]
  28. 28.  Yakovenko ML, Cherkasova EA, Rezapkin GV, Ivanova OE, Ivanov AP et al. 2006. Antigenic evolution of vaccine-derived polioviruses: changes in individual epitopes and relative stability of the overall immunological properties. J. Virol. 80:2641–53
     [Google Scholar]
  29. 29.  Belnap DM, McDermott BM, Filman DJ, Cheng NQ, Trus BL et al. 2000. Three-dimensional structure of poliovirus receptor bound to poliovirus. PNAS 97:73–78
     [Google Scholar]
  30. 30.  He Y, Mueller S, Chipman PR, Bator CM, Peng X et al. 2003. Complexes of poliovirus serotypes with their common cellular receptor, CD155. J. Virol. 77:4827–35
     [Google Scholar]
  31. 31.  Guillot S, Caro V, Cuervo N, Korotkova E, Combiescu M et al. 2000. Natural genetic exchanges between vaccine and wild poliovirus strains in humans. J. Virol. 74:8434–43
     [Google Scholar]
  32. 32.  Liu HM, Zheng DP, Zhang LB, Oberste MS, Kew OM, Pallansch MA 2003. Serial recombination during circulation of type 1 wild-vaccine recombinant polioviruses in China. J. Virol. 77:10994–1005
     [Google Scholar]
  33. 33.  Jegouic S, Joffret ML, Blanchard C, Riquet FB, Perret C et al. 2009. Recombination between polioviruses and co-circulating coxsackie A viruses: role in the emergence of pathogenic vaccine-derived polioviruses. PLOS Pathog 5:e1000412
     [Google Scholar]
  34. 34.  Bodian D 1949. Histopathologic basis of clinical findings in poliomyelitis. Am. J. Med. 6:563–78
     [Google Scholar]
  35. 35.  Wright PF, Wieland-Alter W, Ilyushina NA, Hoen AG, Arita M et al. 2014. Intestinal immunity is a determinant of clearance of poliovirus after oral vaccination. J. Infect. Dis. 209:1628–34
     [Google Scholar]
  36. 36.  Patriarca PA, Sutter RW, Oostvogel PM 1997. Outbreaks of paralytic poliomyelitis, 1976–1995. J. Infect. Dis. 175:Suppl. 1S165–72
     [Google Scholar]
  37. 37.  Patriarca PA, Wright PF, John TJ 1991. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev. Infect. Dis. 13:926–39
     [Google Scholar]
  38. 38.  Landsteiner K, Popper E 1908. Mikroskopische Praparate von einem menschlichen und zwei Affenruckenmarken. Wien. Klin. Wochenschr. 21:1830
     [Google Scholar]
  39. 39.  Vidor E 2018. Poliovirus vaccine—inactivated. Vaccines SA Plotkin, WA Orenstein, PA Offit, KM Edwards 841–65 Philadelphia: Elsevier
     [Google Scholar]
  40. 40.  Robbins FC 2004. The history of polio vaccine development. Vaccines SA Plotkin, WA Orenstein 17–30 Philadelphia: Saunders
     [Google Scholar]
  41. 41. Comm. Typing Natl. Found. Infant. Paralys. 1951. Immunologic classification of poliomyelitis viruses: a cooperative program for the typing of one hundred strains. Am. J. Hyg. 54:191–204
     [Google Scholar]
  42. 42.  Horstmann DM, McCollum RW, Mascola AD 1954. Viremia in human poliomyelitis. J. Exp. Med. 99:355–69
     [Google Scholar]
  43. 43.  Hammon WM, Coriell LL, Wehrle PF, Stokes J Jr 1953. Evaluation of Red Cross gamma globulin as a prophylactic agent for poliomyelitis. IV. Final report of results based on clinical diagnoses. J. Am. Med. Assoc. 151:1272–85
     [Google Scholar]
  44. 44.  Melnick JL 1978. Advantages and disadvantages of the killed and live poliomyelitis vaccines. Bull. World Health Organ. 56:21–38
     [Google Scholar]
  45. 45.  Salk JE, Krech U, Youngner JS, Bennett BL, Lewis LJ, Bazeley PL 1954. Formaldehyde treatment and safety testing of experimental poliomyelitis vaccines. Am. J. Pub. Health 44:563–70
     [Google Scholar]
  46. 46.  Nathanson N, Langmuir AD 1963. The Cutter incident. Poliomyelitis following formaldehyde-inactivated poliovirus vaccination in the United States in the spring of 1955. II. Relationship of poliomyelitis to Cutter vaccine. Am. J. Hyg. 78:29–60
     [Google Scholar]
  47. 47.  Onorato IM, Modlin JF, McBean AM, Thoms ML, Losonsky GA, Bernier RH 1991. Mucosal immunity induced by enhanced-potency inactivated and oral polio vaccines. J. Infect. Dis. 163:1–6
     [Google Scholar]
  48. 48.  Alexander LN, Seward JF, Santibanez TA, Pallansch MA, Kew OM et al. 2004. Vaccine policy changes and epidemiology of poliomyelitis in the United States. J. Am. Med. Assoc. 292:1696–701
     [Google Scholar]
  49. 49.  Sabin AB, Boulger LR 1973. History of Sabin attenuated poliovirus oral live vaccine strains. J. Biol. Stand. 1:115–18
     [Google Scholar]
  50. 50.  Platt LR, Estívariz CF, Sutter RW 2014. Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. J. Infect. Dis. 210:Suppl. 1S380–89
     [Google Scholar]
  51. 51.  Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA 2005. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu. Rev. Microbiol. 59:587–635
     [Google Scholar]
  52. 52.  Burns CC, Diop OM, Sutter RW, Kew OM 2014. Vaccine-derived polioviruses. J. Infect. Dis. 210:Suppl. 1S283–93
     [Google Scholar]
  53. 53.  Jorba J, Diop OM, Iber J, Henderson E, Sutter RW et al. 2017. Update on vaccine-derived polioviruses—worldwide, January 2016–June 2017. Morbid. Mortal. Wkly. Rep. 66:1185–91
     [Google Scholar]
  54. 54.  Schonberger LB, Sullivan-Bolyai JZ, Bryan JA 1978. Poliomyelitis in the United States. Adv. Neurol. 19:217–27
     [Google Scholar]
  55. 55.  Paccaud MF 1979. World trends in poliomyelitis morbidity and mortality, 1951–1975. World Health Stat. Q. 32:198–224
     [Google Scholar]
  56. 56.  Más Lago P 1999. Eradication of poliomyelitis in Cuba: a historical perspective. Bull. World Health Organ. 77:681–87
     [Google Scholar]
  57. 57.  Fenner F, Henderson DA, Arita I, Ježek Z, Ladnyi ID 1988. Smallpox and Its Eradication Geneva: World Health Organ.
  58. 58.  Henderson RH 1984. The Expanded Programme on Immunization of the World Health Organization. Rev. Infect. Dis. 6:Suppl. 2S475–79
     [Google Scholar]
  59. 59.  Risi JB 1984. The control of poliomyelitis in Brazil. Rev. Infect. Dis. 6:Suppl. 2S400–3
     [Google Scholar]
  60. 60. Pan Am. Health Organ. 1985. Director announces campaign to eradicate poliomyelitis from the Americas by 1990. Bull. Pan Am. Health Organ. 19:21–35
     [Google Scholar]
  61. 61. Pan Am. Health Organ. 2016. Region of the Americas is declared free of measles. Immun. Newsl. 38:1–2
     [Google Scholar]
  62. 62.  Grant GB, Reef SE, Patel M, Knapp JK, Dabbagh A 2017. Progress in rubella and congenital rubella syndrome control and elimination—worldwide, 2000–2016. Morbid. Mortal. Wkly. Rep. 66:1256–60
     [Google Scholar]
  63. 63.  Sever JL, McGovern M, Scott R, Pandak C, Edwards A, Goodstone D 2017. Rotary's PolioPlus Program: lessons learned, transition planning, and legacy. J. Infect. Dis. 216:Suppl. 1S355–61
     [Google Scholar]
  64. 64.  Adams A, Boualam L, Diorditsa S, Gregory C, Jee Y et al. 2014. Maintaining polio-free certification in the World Health Organization Western Pacific Region for over a decade. J. Infect. Dis. 210:Suppl. 1S259–67
     [Google Scholar]
  65. 65.  Wang KA, Zhang LB, Otten MW Jr., Zhang XL, Chiba Y et al. 1997. Status of the eradication of indigenous wild poliomyelitis in the People's Republic of China. J. Infect. Dis. 175:Suppl. 1S105–12
     [Google Scholar]
  66. 66.  Dowdle WR, Birmingham ME 1997. The biologic principles of poliovirus eradication. J. Infect. Dis. 175:Suppl. 1S286–92
     [Google Scholar]
  67. 67.  Hull HF, Ward NA, Milstien JB, de Quadros C 1994. Paralytic poliomyelitis: seasoned strategies, disappearing disease. Lancet 343:1331–37
     [Google Scholar]
  68. 68.  Birmingham ME, Linkins RW, Hull BP, Hull HF 1997. Poliomyelitis surveillance: the compass for eradication. J. Infect. Dis. 175:Suppl. 1S146–50
     [Google Scholar]
  69. 69.  Maes EF, Diop OM, Jorba J, Chavan S, Tangermann RH, Wassilak SG 2017. Surveillance systems to track progress toward polio eradication—worldwide, 2015–2016. Morbid. Mortal. Wkly. Rep. 66:359–65
     [Google Scholar]
  70. 70.  Diop OM, Kew OM, de Gourville EM, Pallansch MA 2017. The Global Polio Laboratory Network as a platform for the viral vaccine-preventable and emerging diseases laboratory networks. J. Infect. Dis. 216:Suppl. 1S299–307
     [Google Scholar]
  71. 71.  Kilpatrick DR, Yang CF, Ching K, Vincent A, Iber J et al. 2009. Rapid group-, serotype-, and vaccine strain-specific identification of poliovirus isolates by real-time reverse transcription-PCR using degenerate primers and probes containing deoxyinosine residues. J. Clin. Microbiol. 47:1939–41
     [Google Scholar]
  72. 72.  Gerloff N, Sun H, Mandelbaum M, Maher C, Nix WA et al. 2017. Diagnostic assay development for poliovirus eradication. J. Clin. Microbiol. 56:e01624–17
     [Google Scholar]
  73. 73.  Asghar H, Diop OM, Weldegebriel G, Malik F, Shetty S et al. 2014. Environmental surveillance for polioviruses in the Global Polio Eradication Initiative. J. Infect. Dis. 210:Suppl. 1S294–303
     [Google Scholar]
  74. 74.  Jorba J, Campagnoli R, De L, Kew O 2008. Calibration of multiple poliovirus molecular clocks covering an extended evolutionary range. J. Virol. 82:4429–40
     [Google Scholar]
  75. 75.  Martín J, Dunn G, Hull R, Patel V, Minor PD 2000. Evolution of the Sabin strain of type 3 poliovirus in an immunodeficient patient during the entire 637-day period of virus excretion. J. Virol. 74:3001–10
     [Google Scholar]
  76. 76.  Yang CF, Chen HY, Jorba J, Sun HC, Yang SJ et al. 2005. Intratypic recombination among lineages of type 1 vaccine-derived poliovirus emerging during chronic infection of an immunodeficient patient. J. Virol. 79:12623–34
     [Google Scholar]
  77. 77.  Landaverde JM, Trumbo SP, Danovaro-Holliday MC, Cochi SE, Gandhi R, Ruiz-Matus C 2014. Vaccine-associated paralytic poliomyelitis in the postelimination era in Latin America and the Caribbean, 1992–2011. J. Infect. Dis. 209:1393–402
     [Google Scholar]
  78. 78.  Khetsuriani N, Pfeifer D, Deshevoi S, Gavrilin E, Shefer A et al. 2014. Challenges of maintaining polio-free status of the European Region. J. Infect. Dis. 210:Suppl. 1S194–207
     [Google Scholar]
  79. 79. World Health Organ. 2001. Progress toward global poliomyelitis eradication, 2000. Wkly. Epidemiol. Rec. 76:126–31
     [Google Scholar]
  80. 80.  Tangermann RH, Hull HF, Jafari H, Nkowane B, Everts H, Aylward RB 2000. Eradication of poliomyelitis in countries affected by conflict. Bull. World Health Organ. 78:330–38
     [Google Scholar]
  81. 81.  Nnadi C, Etsano A, Uba B, Ohuabunwo C, Melton M et al. 2017. Approaches to vaccination among populations in areas of conflict. J. Infect. Dis. 216:Suppl. 1S368–72
     [Google Scholar]
  82. 82.  Kew OM, Pallansch MA 2002. The mechanism of polio eradication. Molecular Biology of Picornaviruses BL Semler, E Wimmer 481–91 Washington, DC: ASM Press
     [Google Scholar]
  83. 83. Cent. Dis. Control Prev. 2009. Wild poliovirus type 1 and type 3 importations—15 countries, Africa, 2008–2009. Morbid. Mortal. Wkly. Rep. 58:357–62
     [Google Scholar]
  84. 84.  Mbaeyi C, Kamadjeu R, Mahamud A, Webeck J, Ehrhardt D, Mulugeta A 2014. Progress toward polio eradication—Somalia, 1998–2013. J. Infect. Dis. 210:Suppl. 1S173–80
     [Google Scholar]
  85. 85.  Hagan JE, Wassilak SGF, Craig AS, Tangermann RH, Diop OM et al. 2015. Progress toward polio eradication—worldwide, 2014–2015. Morbid. Mortal. Wkly. Rep. 64:527–31
     [Google Scholar]
  86. 86.  Morales M, Tangermann RH, Wassilak SG 2016. Progress toward polio eradication—worldwide, 2015–2016. Morbid. Mortal. Wkly. Rep. 65:470–73
     [Google Scholar]
  87. 87. World Health Organ. 1996. Progress towards poliomyelitis eradication, Indonesia, 1995. Wkly. Epidemiol. Rec. 71:253–55
     [Google Scholar]
  88. 88. World Health Organ. 1999. Final stages of polio eradication WHO Western Pacific Region, 1997–1998. Wkly. Epidemiol. Rec. 74:20–24
     [Google Scholar]
  89. 89.  O'Connor PM, Allison R, Thapa A, Bahl S, Chunsuittiwat S et al. 2014. Update on polio eradication in the World Health Organization South-East Asia Region, 2013. J. Infect. Dis. 210:Suppl. 1S216–24
     [Google Scholar]
  90. 90.  Martinez M, Shukla H, Nikulin J, Wadood MZ, Hadler S et al. 2017. Progress toward poliomyelitis eradication—Afghanistan, January 2016–June 2017. Morbid. Mortal. Wkly. Rep. 66:854–58
     [Google Scholar]
  91. 91.  Elhamidi Y, Mahamud A, Safdar M, Al Tamimi W, Jorba J et al. 2017. Progress toward poliomyelitis eradication—Pakistan, January 2016–September 2017. Morbid. Mortal. Wkly. Rep. 66:1276–80
     [Google Scholar]
  92. 92.  Etsano A, Gunnala R, Shuaib F, Damisa E, Mkanda P et al. 2015. Progress toward poliomyelitis eradication—Nigeria, January 2014–July 2015. Morbid. Mortal. Wkly. Rep. 64:878–82
     [Google Scholar]
  93. 93.  Kew O 2012. Reaching the last one per cent: progress and challenges in global polio eradication. Curr. Opin. Virol. 2:188–98
     [Google Scholar]
  94. 94.  Mach O, Tangermann RH, Wassilak SG, Singh S, Sutter RW 2014. Outbreaks of paralytic poliomyelitis during 1996–2012: the changing epidemiology of a disease in the final stages of eradication. J. Infect. Dis. 210:Suppl. 1S275–82
     [Google Scholar]
  95. 95. World Health Organ. 2003. Progress towards poliomyelitis eradication in India, 2002. Wkly. Epidemiol. Rec. 78:66–71
     [Google Scholar]
  96. 96. World Health Organ. 2003. Progress towards poliomyelitis eradication in Nigeria, January 2002 to March 2003. Wkly. Epidemiol. Rec. 78:210–15
     [Google Scholar]
  97. 97. World Health Organ. 2004. Progress towards poliomyelitis eradication in India, 2003. Wkly. Epidemiol. Rec. 79:121–25
     [Google Scholar]
  98. 98. World Health Organ. 2004. Progress towards global eradication of poliomyelitis, 2003 and January–April 2004. Wkly. Epidemiol. Rec. 79:229–34
     [Google Scholar]
  99. 99. World Health Organ. 2004. Progress towards poliomyelitis eradication in Nigeria, January 2003–March 2004. Wkly. Epidemiol. Rec. 79:162–67
     [Google Scholar]
  100. 100. Cent. Dis. Control Prev. 2006. Resurgence of wild poliovirus type 1 transmission and consequences of importation—21 countries, 2002–2005. Morbid. Mortal. Wkly. Rep. 55:145–50
     [Google Scholar]
  101. 101.  Grassly NC, Wenger J, Durrani S, Bahl S, Deshpande JM et al. 2007. Protective efficacy of a monovalent oral type 1 poliovirus vaccine: a case-control study. Lancet 369:1356–62
     [Google Scholar]
  102. 102.  El-Sayed N, El-Gamal Y, Abbassy AA, Seoud I, Salama M et al. 2008. Monovalent type 1 oral poliovirus vaccine in newborns. N. Engl. J. Med. 359:1655–65
     [Google Scholar]
  103. 103. World Health Organ. 2008. Progress towards interrupting of wild poliovirus transmission worldwide, January 2007–April 2008. Wkly. Epidemiol. Rec. 83:170–76
     [Google Scholar]
  104. 104. World Health Organ. 2010. Progress towards eradicating poliomyelitis in India, January 2009–October 2010. Wkly. Epidemiol. Rec. 85:497–503
     [Google Scholar]
  105. 105.  Patel MK, Konde MK, Didi-Ngossaki BH, Ndinga E, Yogolelo R et al. 2012. An outbreak of wild poliovirus in the Republic of Congo, 2010–2011. Clin. Infect. Dis. 55:1291–98
     [Google Scholar]
  106. 106. World Health Organ. 2012. Progress towards eradicating poliomyelitis: Afghanistan and Pakistan, January 2011–August 2012. Wkly. Epidemiol. Rec. 87:381–88
     [Google Scholar]
  107. 107.  Mbaeyi C, Ryan MJ, Smith P, Mahamud A, Farag N et al. 2017. Response to a large polio outbreak in a setting of conflict—Middle East, 2013–2015. Morbid. Mortal. Wkly. Rep. 66:227–31
     [Google Scholar]
  108. 108.  Shulman LM, Mendelson E, Anis E, Bassal R, Gdalevich M et al. 2014. Laboratory challenges in response to silent introduction and sustained transmission of wild poliovirus type 1 in Israel during 2013. J. Infect. Dis. 210:Suppl. 1S304–14
     [Google Scholar]
  109. 109.  Anis E, Kopel E, Singer SR, Kaliner E, Moerman L et al. 2013. Insidious reintroduction of wild poliovirus into Israel, 2013. Eurosurveillance 18:20586
     [Google Scholar]
  110. 110.  John TJ 1984. Poliomyelitis in India: prospects and problems of control. Rev. Infect. Dis. 6:S438–41
     [Google Scholar]
  111. 111.  Nnadi C, Damisa E, Esapa L, Braka F, Waziri N et al. 2017. Continued endemic wild poliovirus transmission in security-compromised areas—Nigeria, 2016. Morbid. Mortal. Wkly. Rep. 66:190–93
     [Google Scholar]
  112. 112.  Alam MM, Sharif S, Shaukat S, Angez M, Khurshid A et al. 2016. Genomic surveillance elucidates persistent wild poliovirus transmission during 2013–2015 in major reservoir areas of Pakistan. Clin. Infect. Dis. 62:190–98
     [Google Scholar]
  113. 113.  Farag NH, Wadood MZ, Safdar RM, Ahmed N, Hamdi S et al. 2015. Progress toward poliomyelitis eradication—Pakistan, January 2014–September 2015. Morbid. Mortal. Wkly. Rep. 64:1271–75
     [Google Scholar]
  114. 114. World Health Organ. 2013. Progress towards global interruption of wild poliovirus transmission, January 2012–March 2013. Wkly. Epidemiol. Rec. 88:181–87
     [Google Scholar]
  115. 115.  Alexander JP Jr., Gary HE Jr., Pallansch MA 1997. Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance: a review of the literature. J. Infect. Dis. 175:Suppl. 1S176–82
     [Google Scholar]
  116. 116.  DeVries AS, Harper J, Murray A, Lexau C, Bahta L et al. 2011. Vaccine-derived poliomyelitis 12 years after infection in Minnesota. N. Engl. J. Med. 364:2316–23
     [Google Scholar]
  117. 117.  Dunn G, Klapsa D, Wilton T, Stone L, Minor PD, Martín J 2015. Twenty-eight years of poliovirus replication in an immunodeficient individual: impact on the global polio eradication initiative. PLOS Pathog 11:e1005114
     [Google Scholar]
  118. 118.  Burns C, Shaw J, Jorba J, Bukbuk D, Adu F et al. 2013. Multiple independent emergences of type 2 vaccine-derived polioviruses during a large outbreak in northern Nigeria. J. Virol. 87:4907–22
     [Google Scholar]
  119. 119.  Jenkins HE, Aylward RB, Gasasira A, Donnelly CA, Mwanza M et al. 2010. Implications of a circulating vaccine-derived poliovirus in Nigeria. N. Engl. J. Med. 362:2360–69
     [Google Scholar]
  120. 120. World Health Organ. 2016. Ebola Outbreak, 2014–2015 Rep. World Health Organ. Geneva: http://www.who.int/csr/disease/ebola/en/
  121. 121.  Jorba J, Diop OM, Iber J, Sutter RW, Wassilak SG, Burns CC 2016. Update on vaccine-derived polioviruses—worldwide, January 2015–May 2016. Morbid. Mortal. Wkly. Rep. 65:763–69
     [Google Scholar]
  122. 122.  Macklin G, Liao Y, Takane M, Dooling K, Gilmour S et al. 2017. Prolonged excretion of poliovirus among individuals with primary immunodeficiency disorder: an analysis of the World Health Organization registry. Front. Immunol. 8:1103
     [Google Scholar]
  123. 123.  Li L, Ivanova O, Triki H, Tiongco-Recto M, da Silva R et al. 2014. Poliovirus excretion among persons with primary immune deficiency disorders: Summary of a seven-country study series. J. Infect. Dis. 210:Suppl. 1S368–72
     [Google Scholar]
  124. 124.  Hennessey KA, Lago H, Diomande F, Akoua-Koffi C, Cáceres VM et al. 2005. Poliovirus vaccine shedding among persons with HIV in Abidjan, Cote d'Ivoire. J. Infect. Dis. 192:2124–28
     [Google Scholar]
  125. 125.  Khetsuriani N, Helfand R, Pallansch M, Kew O, Fowlkes A et al. 2009. Limited duration of vaccine poliovirus and other enterovirus excretion among human immunodeficiency virus infected children in Kenya. BMC Infect. Dis. 9:136
     [Google Scholar]
  126. 126.  McKinlay MA, Collett MS, Hincks JR, Oberste MS, Pallansch MA et al. 2014. Progress in the development of poliovirus antiviral agents and their essential role in reducing risks that threaten eradication. J. Infect. Dis. 210:Suppl. 1S447–53
     [Google Scholar]
  127. 127.  Collett MS, Hincks JR, Benschop K, Duizer E, van der Avoort H et al. 2017. Antiviral activity of pocapavir in a randomized, blinded, placebo-controlled human oral poliovirus vaccine challenge model. J. Infect. Dis. 215:335–43
     [Google Scholar]
  128. 128. Glob. Polio Erad. Init. 2013. Polio Eradication and Endgame Strategic Plan (2013–2018) Geneva: World Health Organ. Glob. Polio Erad. Init http://polioeradication.org/wp-content/uploads/2016/07/PEESP_EN_A4.pdf
  129. 129.  Zipursky S, Patel M, Farrell M, Gonzalez AR, Kachra T et al. 2017. Lessons learned from managing the planning and implementation of inactivated polio vaccine introduction in support of the Polio Endgame. J. Infect. Dis. 216:Suppl. 1S15–23
     [Google Scholar]
  130. 130.  Okayasu H, Sein C, Chang Blanc D, Gonzalez AR, Zehrung D et al. 2017. Intradermal administration of fractional doses of inactivated poliovirus vaccine: a dose-sparing option for polio immunization. J. Infect. Dis. 216:Suppl. 1S161–67
     [Google Scholar]
  131. 131.  Okayasu H, Sein C, Hamidi A, Bakker WA, Sutter RW 2016. Development of inactivated poliovirus vaccine from Sabin strains: a progress report. Biologicals 44:581–87
     [Google Scholar]
  132. 132.  Ramirez Gonzalez A, Farrell M, Menning L, Garon J, Everts H et al. 2017. Implementing the synchronized global switch from trivalent to bivalent oral polio vaccines—lessons learned from the global perspective. J. Infect. Dis. 216:Suppl. 1S183–92
     [Google Scholar]
  133. 133.  Farrell M, Hampton LM, Shendale S, Menning L, Gonzalez AR et al. 2017. Monitoring and validation of the global replacement of tOPV with bOPV, April–May 2016. J. Infect. Dis. 216:Suppl. 1S193–201
     [Google Scholar]
  134. 134.  Hampton LM, Farrell M, Ramirez-Gonzalez A, Menning L, Shendale S et al. 2016. Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine—worldwide, 2016. Morbid. Mortal. Wkly. Rep. 65:934–38
     [Google Scholar]
  135. 135.  Wanyoike S, Ramirez Gonzalez A, Dolan SB, Garon J, Veira CL et al. 2017. Disposing of excess vaccines after the withdrawal of oral polio vaccine. J. Infect. Dis. 216:Suppl. 1S202–8
     [Google Scholar]
  136. 136.  Previsani N, Singh H, St. Pierre J, Boualam L, Fournier-Caruana J et al. 2017. Progress toward containment of poliovirus type 2—worldwide, 2017. Morbid. Mortal. Wkly. Rep. 66:649–52
     [Google Scholar]
  137. 137.  Bahl S, Hampton LM, Bhatnagar P, Rao GS, Haldar P et al. 2017. Notes from the field: detection of Sabin-like type 2 poliovirus from sewage after global cessation of trivalent oral poliovirus vaccine—Hyderabad and Ahmedabad, India, August–September 2016. Morbid. Mortal. Wkly. Rep. 65:1493–94
     [Google Scholar]
  138. 138.  Hampton LM, du Chatellier GM, Fournier-Caruana J, Ottosen A, Rubin J et al. 2017. Considerations for the full global withdrawal of oral polio vaccine after eradication of polio. J. Infect. Dis. 216:Suppl. 1S217–25
     [Google Scholar]
  139. 139.  Macadam AJ, Ferguson G, Stone DM, Meredith J, Knowlson S et al. 2006. Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: relevance to poliomyelitis eradication. J. Virol. 80:8653–63
     [Google Scholar]
  140. 140.  Pfeiffer JK, Kirkegaard K 2006. Bottleneck-mediated quasispecies restriction during spread of an RNA virus from inoculation site to brain. PNAS 103:5520–25
     [Google Scholar]
  141. 141.  Vignuzzi M, Wendt E, Andino R 2008. Engineering attenuated virus vaccines by controlling replication fidelity. Nat. Med. 14:154–61
     [Google Scholar]
  142. 142.  Burns CC, Campagnoli R, Shaw J, Vincent A, Jorba J, Kew O 2009. Genetic inactivation of poliovirus infectivity by increasing the frequencies of CpG and UpA dinucleotides within and across synonymous capsid region codons. J. Virol. 83:9957–69
     [Google Scholar]
  143. 143.  Sanders BP, de Los Rios Oakes I, van Hoek V, Bockstal V, Kamphuis T et al. 2016. Cold-adapted viral attenuation (CAVA): highly temperature sensitive polioviruses as novel vaccine strains for a next generation inactivated poliovirus vaccine. PLOS Pathog 12:e1005483
     [Google Scholar]
  144. 144.  Adeyemi OO, Nicol C, Stonehouse NJ, Rowlands DJ 2017. Increasing type 1 poliovirus capsid stability by thermal selection. J. Virol. 91:e01586–16
     [Google Scholar]
  145. 145. World Health Organ. 2015. WHO Global Action Plan to Minimize Poliovirus Facility-Associated Risk After Type-Specific Eradication of Wild Polioviruses and Sequential Cessation of Oral Polio Vaccine Use (GAPIII) Geneva: World Health Organ http://apps.who.int/iris/bitstream/handle/10665/208872/WHO_POLIO_15.05_eng.pdf
  146. 146.  Smith J, Leke R, Adams A, Tangermann RH 2004. Certification of polio eradication: process and lessons learned. Bull. World Health Organ. 82:24–30
     [Google Scholar]
  147. 147.  Previsani N, Tangermann RH, Tallis G, Jafari HS 2015. World Health Organization guidelines for containment of poliovirus following type-specific polio eradication—worldwide, 2015. Morbid. Mortal. Wkly. Rep. 64:913–17
     [Google Scholar]
  148. 148.  Rutter PD, Hinman AR, Hegg L, King D, Sosler S et al. 2017. Transition planning for after polio eradication. J. Infect. Dis. 216:Suppl. 1S287–92
     [Google Scholar]
  149. 149.  Vaz RG, Mkanda P, Banda R, Komkech W, Ekundare-Famiyesin OO et al. 2016. The role of the polio program infrastructure in response to Ebola virus disease outbreak in Nigeria 2014. J. Infect. Dis. 213:Suppl. 3S140–46
     [Google Scholar]
  150. 150.  Mulders MN, Serhan F, Goodson JL, Icenogle J, Johnson BW, Rota PA 2017. Expansion of surveillance for vaccine-preventable diseases: building on the Global Polio Laboratory Network and the Global Measles and Rubella Laboratory Network platforms. J. Infect. Dis. 216:Suppl. 1S324–30
     [Google Scholar]
/content/journals/10.1146/annurev-virology-101416-041749
Loading
Breaking the Last Chains of Poliovirus Transmission: Progress and Challenges in Global Polio Eradication
Annual Review of Virology 5, 427 (2018); https://doi.org/10.1146/annurev-virology-101416-041749
/content/journals/10.1146/annurev-virology-101416-041749
/content/journals/10.1146/annurev-virology-101416-041749
Loading

Data & Media loading...

Supplemental Material

Supplementary Data

  • Download all Supplemental Material as a single PDF. Includes Supplemental Table 1, Supplemental Figures 1-8, and associated references.

  • Article Type: Review Article

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error